How Can the Immune System Cause a Perfect Embryo to Fail?

The embryo carries half its DNA from the father, which makes it genetically foreign to the mother’s body in the same way a transplanted organ would be, and for implantation to succeed the uterine immune environment needs to shift from its default defensive mode into active tolerance, a shift that fails in some women for reasons their fertility clinic never tested for because the tests were not part of the standard panel.

• NK cells turning aggressive at the implantation site: Uterine natural killer cells are supposed to remodel blood vessels around the implanting embryo to help it establish a blood supply, but in some patients these cells attack the trophoblast instead, and a study of 283 women with repeated implantation failure found that those with abnormal NK profiles had implantation rates of 12.3 percent compared to 24.9 percent in women with normal levels, a gap that closed completely when the abnormal group received IVIG before their next transfer.
• Tiny blood clots choking the implantation site: Antiphospholipid antibodies cause microscopic clotting in the small vessels forming at the point where the embryo tries to embed, cutting off the blood supply before the pregnancy ever registers on a test, and the frustrating part is that APA testing is cheap, widely available, and takes a single blood draw, yet most Indian fertility clinics still do not include it in their standard recurrent failure panel despite it being one of the most treatable immune causes once identified.
• The wrong type of immune response dominating: Successful pregnancy requires a shift from TH1 inflammatory responses toward TH2 tolerance responses at the uterine level, and women whose cytokine profiles show elevated TNF-alpha and interferon-gamma maintain an inflammatory environment that essentially treats the embryo as something dangerous rather than something to nurture, a pattern that explains why some patients miscarry repeatedly after getting positive tests while others never implant at all.
• Thyroid antibodies amplifying everything else: About half of women who test positive for antithyroid antibodies also show elevated NK cell activity, and this combination creates a more hostile implantation environment than either condition alone, which matters practically because thyroid antibody testing is routine in most Indian clinics while the NK cell testing that would reveal the compounding effect almost never accompanies it through standard IUI treatment or IVF panels.

Women undergoing IVF treatment in India who have had 3 or more failed transfers with good-quality embryos should ask whether immune testing has been considered, because the standard workup at most clinics does not include it and the conversation will not happen unless someone in the room initiates it.

What Can Actually Be Done Once an Immune Problem Is Found?

Reproductive immunology sits in that uncomfortable professional space where the biology makes sense, some of the clinical results are genuinely encouraging, and the definitive trials that would end the debate have not been run, which is why one clinic dismisses it entirely while the clinic across the street offers immune panels to everyone after a single failed transfer, and both can point to published literature supporting their position depending on which papers they choose to cite.

• Steroids prescribed by clinics that deny practicing immunology: Low-dose prednisolone around transfer is the most common immune intervention in IVF, and the irony is that many mainstream clinics prescribe it as a standard precaution while simultaneously claiming they do not practice reproductive immunology, which means they are treating an immune problem they officially do not believe exists, a contradiction that patients rarely notice but that says something meaningful about where the field actually stands versus where it claims to stand.
• Intralipid as the financially realistic option: A fat emulsion dripped intravenously before transfer suppresses NK cell activity, costs a fraction of IVIG, carries minimal risk, and has been adopted by Indian fertility clinics as the pragmatic middle ground for patients who cannot afford the gold-standard immune treatment but whose NK cell profiles suggest doing nothing is not the right answer either, making it the intervention that gets prescribed most often on the basis of “the evidence is limited but the downside of trying is close to zero.”
• IVIG for documented NK cell abnormalities: Intravenous immunoglobulin modulates the full immune response and the 283-patient study showed implantation rates in the abnormal NK group climbing from 12.3 to 27.5 percent after IVIG, but each infusion costs 50,000 to over 1 lakh rupees in India and most patients need multiple doses, which means the treatment with the best published data is accessible only to couples whose finances can absorb another lakh on top of what they have already spent on cycles that produced nothing.
• Heparin and aspirin for APA-positive patients: Low-molecular-weight heparin plus baby aspirin prevents the microclotting that antiphospholipid antibodies cause at the implantation site, and unlike every other immune intervention in fertility this one actually has enough evidence behind it that professional guidelines endorse it rather than hedging about it, making it the single immune treatment where the patient does not have to weigh experimental hope against financial risk because the clinical consensus has already landed on the side of prescribing it.

The challenge in India is that immune testing panels cost 5,000 to 20,000 rupees per marker and treatment adds significantly to cycles already running into lakhs, and women managing IVF Injections alongside repeated failure need a doctor who orders immune workups when the clinical pattern warrants investigation rather than reflexively after every failed transfer or never at all regardless of how many good embryos have failed to implant. Any good IVF center in India approaches reproductive immunology the way it approaches every other diagnostic question, by testing when the clinical picture points in that direction and not before.

Why Choose Dr. Manisha Mehta?

Dr. Manisha Mehta has investigated immune causes in patients whose repeated failures made no sense through any standard diagnostic lens across her 20-year career, and her 85% IVF success rate includes patients who tested positive for elevated NK cells or antiphospholipid antibodies and conceived after targeted immune treatment that their previous clinic never thought to look for. Recognised among the best IVF specialists in India for ordering immune panels to answer a specific clinical question rather than as a revenue-generating add-on to every failed cycle, she treats reproductive immunology as a diagnostic tool with a specific indication rather than a net cast over every patient who did not get pregnant on the first attempt.

Call Now: +91 91680 39000